Edition:
United Kingdom

aTyr Pharma Inc (LIFE.OQ)

LIFE.OQ on NASDAQ Stock Exchange Global Select Market

3.55USD
13 Dec 2017
Change (% chg)

$-0.08 (-2.07%)
Prev Close
$3.62
Open
$3.60
Day's High
$3.65
Day's Low
$3.50
Volume
13,085
Avg. Vol
11,695
52-wk High
$6.45
52-wk Low
$2.12

Summary

Name Age Since Current Position

John Clarke

63 2005 Independent Chairman of the Board

Sanjay Shukla

45 2017 President, Chief Executive Officer, Chief Medical Officer

John Blake

40 2017 Senior Vice President - Finance

David King

58 2016 Senior Vice President - Research

Grove Matsuoka

58 2016 Senior Vice President, Product Programs and Planning

Ashraf Amanullah

49 2015 Vice President, Biologics Development and Manufacturing

Sanuj Ravindran

45 2016 Chief Business Officer

Timothy Coughlin

50 2017 Director

Jeffrey Hatfield

2017 Director

John Mendlein

57 2017 Director

Srinivas Akkaraju

48 2015 Independent Director

James Blair

77 2010 Independent Director

Amir Nashat

44 2006 Independent Director

Paul Schimmel

76 2005 Independent Director

Biographies

Name Description

John Clarke

Mr. John K. Clarke is Independent Chairman of the Board of the Company. Mr. Clarke is Managing Partner of Cardinal Partners, a venture capital firm focused on healthcare investing. He co-founded Cardinal Partners in 1997 and has served as President of CHP Management, Inc. since that time. He currently serves as a director on the boards of Alnylam Pharmaceuticals, Inc., a publicly traded biopharmaceutical company and various privately held biotechnology companies which including Abide Therapeutics, Inc., Vividion Therapeutics, Inc. and Ivenix Corporation. He has also served as a director for several biotechnology and biopharmaceutical companies including Momenta Pharmaceuticals, Inc., Verastem, Inc. and Sirtris Pharmaceuticals, Inc. (acquired by GlaxoSmithKline); healthcare information technology companies including TechRx Technology Services Corporation (acquired by NDCHealth) and Visicu, Inc. (acquired by Phillips Electronics); and a privately held biopharmaceutical company, Rib-X Pharmaceuticals Inc. Mr. Clarke holds an A.B. in economics and biology from Harvard University and an M.B.A. from the Wharton School at the University of Pennsylvania.

Sanjay Shukla

Dr. Sanjay Shukla, M.D., is President, Chief Executive Officer, Chief Medical Officer of the Company. Dr. Shukla worked in an advisory capacity for a number of companies, including as a consultant to aTyr Pharma from January 2016 to March 2016. Prior to that, from October 2012 to April 2015, Dr. Shukla served as Vice President and Global Head of Integrated Medical Services for Novartis, a biopharmaceutical company, where he led global medical affairs operations, with oversight for all pharma general medicines therapies, both inline and in development. Dr. Shukla served as Chief Executive Officer of RxMD, a clinical development consultancy that assisted in advancing proof of concept for early stage drug candidates, from April 2009 to September 2012. Prior to that, Dr. Shukla served in a variety of clinical development, data analytics and drug safety roles at Vifor Pharma, a biopharmaceutical company, and Aspreva Pharmaceuticals (acquired by Vifor Pharma). Dr. Shukla received his M.D. from Howard University College of Medicine and his Bachelors of Science and Master of Science in Epidemiology and Biostatistics from the University of Maryland.

John Blake

Mr. John T. Blake is Senior Vice President - Finance of the Company. Mr. Blake served as the Director, Financial Planning and Analysis of Volcano Corporation, a publicly traded medical device company, from March 2010 to March 2015 and as the SEC Reporting Manager from November 2008 through March 2010. From April 2007 to November 2008, Mr. Blake served in various senior finance roles at Entropic Communications, a semiconductor company. Prior to 2007, Mr. Blake served as an auditor in public accounting and an analyst for BD Biosciences. Mr. Blake is a Certified Public Accountant and holds a Bachelor of Business Administration with a concentration in Accountancy from National University.

David King

Dr. David J. King, Ph.D., is Senior Vice President - Research of the Company. Dr. King has served as our Senior Vice President, Research since September 2016. David’s industry experience is highlighted by his tenures at Medarex, Inc. (acquired by Bristol-Myers Squibb in 2009) and Celltech Therapeutics Ltd. (acquired by UCB in 2004). At Medarex, he led programs to identify therapeutic antibodies and played a key role in programs targeting novel biologics (including PD-1), and at Celltech, he directed the protein biochemistry and antibody engineering activities that led to the discovery and development of Cimzia® (TNF antagonist). After Medarex, Dr. King served as Chief Scientific Officer at AnaptysBio, Inc. from November 2008 to February 2016 where he led research that developed a novel technology for generating antibody therapeutics, which was successfully used to generate innovative clinical candidates for a number of pharmaceutical partnerships and for internal development. Most recently, Dr. King served as Senior Vice President of Research at Tunitas Therapeutics, where he led the company’s research and preclinical activities from February 2016 to September 2016. Dr. King received his B.S. from the University of Warwick and his Ph.D. from the University of Surrey, both in the United Kingdom, and was a Glaxo Group Research postdoctoral fellow.

Grove Matsuoka

Mr. Grove Matsuoka is Senior Vice President, Product Programs and Planning of the Company. Mr. Matsuoka served as Senior Vice President, Commercialization at CoDa Therapeutics, Inc., a biopharmaceutical company, from 2007 to 2016, where he led the development of commercialization plans for novel cellular gap junction modulating platform technology through in-depth assessment of the market, competitive environment, regulatory and market access hurdles. Prior to that, from 1995 to 2007, he worked in various positions at Amgen, Inc., most recently as Director, Medical Affairs, Strategic Planning and Operations, where he established and managed the strategic and operational function for the newly formed Medical Affairs organization. Mr. Matsuoka was also Clinical Research Project Team Leader for an Fc Fusion Program while at Amgen. He received his M.B.A. from Boston College and his B.A. in Microbiology and Immunology from University of California, Berkeley.

Ashraf Amanullah

Dr. Ashraf Amanullah, Ph.D., is Vice President, Biologics Development and Manufacturing of the Company. He served as Senior Director at Gilead Sciences from September 2011 to August 2015, a biopharmaceutical company, where he was responsible for CMC operations for Biologics overseeing drug substance, analytical operations, quality controls, formulations, drug product and device development as well as external manufacturing operations. Prior to Gilead, Dr. Amanullah was Director of Process Development at Genentech from September 2006 to August 2011, a biotechnology company, with responsibility for process development for early stage therapeutics and support of late stage and post approval process development. Dr. Amanullah has also held various positions at Merck & Co. Inc., a global health care company, over a nine year tenure with responsibility for vaccines process development, clinical manufacturing and commercialization support. He is the author of 55 peer-reviewed publications. Dr. Amanullah received his Ph.D. in Chemical Engineering from The University of Birmingham (U.K.) and conducted post-doctoral studies with Novo Nordisk and University College London/Merck & Co. Inc.

Sanuj Ravindran

Dr. Sanuj K. Ravindran, M.D., is no longer a Chief Business Officer of the Company effective December 31, 2017. Dr. Ravindran was Senior Vice President, Corporate Development for The Medicines Company, a biopharmaceutical company, and responsible for Business Development, Competitive Intelligence, and Alliance Management. From January 2010 to June 2012, Dr. Ravindran was a co-founder and Managing Director of Asian Healthcare Fund, a New Delhi based private equity fund focused exclusively on healthcare and life sciences in India. As a Principal of Radius Ventures from 2007 to 2010, Dr. Ravindran invested in and assumed Board roles with several biotechnology companies. Prior to Radius, Dr. Ravindran was a Director of Burrill & Company and also the Healthcare Investment Banking Group at Merrill Lynch. Dr. Ravindran is trained in Internal Medicine and completed his residency training at Thomas Jefferson University Hospital. He was a National Cancer Institute Research Fellow at Memorial Sloan Kettering Cancer Center. He is a member of the Society of Kauffman Fellows and remains a Venture Partner with Asian Healthcare Fund. Dr. Ravindran received a B.A. with Honors from Northwestern University, his M.D. from Jefferson Medical College, and his M.B.A. from the Kellogg School of Management.

Timothy Coughlin

Mr. Timothy P. Coughlin, CPA., is Director of the Company. Mr. Coughlin served as Chief Financial Officer of Neurocrine Biosciences, Inc. from September 2006 to February 2017, where he previously served as Vice President, Controller. Prior to joining Neurocrine in 2002, he was with Catholic Health Initiatives, a nationwide integrated healthcare delivery system, where he served as Vice President, Financial Services. Mr. Coughlin also served as a Senior Manager in the Health Sciences practice of Ernst & Young LLP and its predecessors from 1989 to 1999. Mr. Coughlin currently serves on the board of directors of Retrophin, Inc. and Fate Therapeutics, Inc., two biotechnology companies where he chairs the audit committees and is a member of the compensation committee and nominating committee. Mr. Coughlin holds a master’s degree in international business from San Diego State University and a bachelor’s degree in accounting from Temple University and is a certified public accountant in both California and Pennsylvania.

Jeffrey Hatfield

Mr. Jeffrey S. Hatfield is Director of the Company. Mr. Hatfield most recently served as President, Chief Executive Officer and a member of the Board of Directors of Vitae Pharmaceuticals (“Vitae”) from 2004 to 2016. Mr. Hatfield took Vitae public in 2014, and in October 2016, Vitae was acquired by Allergan plc. Prior to joining Vitae, Mr. Hatfield worked at Bristol-Myers Squibb in a variety of executive positions, including: Senior Vice President of BMS’s Immunology and Virology Divisions, where he was responsible for all aspects of the $1 billion business; President and General Manager, Canada; and Vice President, U.S. Managed Health Care. He previously served as a Board member of Ambit Biosciences before its acquisition by Daiichi-Sankyo in 2015, and as a member of the Board of Directors of the Biotechnology Industry Organization (BIO), serving on the Executive Company Section. Mr. Hatfield currently serves as a Board member of InVivo Therapeutics, a biotechnology company, and as a member of the Advisory Committees for: Purdue University’s College of Pharmacy, where he is a Distinguished Alumni and is on faculty; Drexel University’s LeBow College of Business; and the Chapman-KGI School of BioPharmacy. Mr. Hatfield holds an M.B.A. from The Wharton School, University of Pennsylvania and a bachelor’s degree in Pharmacy from Purdue University.

John Mendlein

Dr. John D. Mendlein, Ph.D., is Director of the Company. Mendlein served as our Executive Chairman of the Board of Directors from July 2010 to December 2015. Dr. Mendlein is Vice Chairman of the Board of Fate Therapeutics, Inc., a biopharmaceutical company, and also holds board positions with Editas Medicine, Inc., Moderna Therapeutics, Inc. and Axcella Health, Inc., which are all biopharmaceutical companies. Dr. Mendlein also serves on the Biotechnology Industry Organization ("BIO") emerging companies board. Dr. Mendlein previously served as the Chief Executive Officer of Adnexus Therapeutics, Inc., a biopharmaceutical company, from 2005 to 2008, which was purchased by Bristol-Myers Squibb Company in 2008. Dr. Mendlein also served on the board of directors of Monogram Biosciences, Inc., an HIV and oncology diagnostic company that was acquired by Laboratory Corporation of America Holdings in 2009. Before that, he served as Chairman and Chief Executive Officer of Affinium Pharmaceuticals, Ltd. (acquired by Debiopharm Group) from 2000 to 2005, and as a board member, General Counsel and Chief Knowledge Officer at Aurora Bioscience Corporation (acquired by Vertex Pharmaceuticals), a biotechnology company, from August 1996 to September 2001. Dr. Mendlein holds a Ph.D. in physiology and biophysics from the University of California, Los Angeles, a J.D. from the University of California, Hastings College of the Law, and a B.S. in biology from the University of Miami. Dr. Mendlein is the co-author or co-inventor of over 210 publications and published patents, including a number of patents associated with our company.

Srinivas Akkaraju

Dr. Srinivas Akkaraju, M.D. Ph.D., is Independent Director of the Company. He is a Founder and Managing General Partner at Samsara BioCapital, L.P. Dr. Akkaraju served as a general partner of Sofinnova Ventures, from April 2013 to February 2016. From January 2009 to April 2013, Dr. Akkaraju served as Managing Director of New Leaf Venture Partners. From August 2006 to December 2008, Dr. Akkaraju served as a Managing Director at Panorama Capital, LLC, a private equity firm founded by the former venture capital investment team of J.P. Morgan Partners, LLC, a private equity division of JPMorgan Chase & Co. Prior to co-founding Panorama Capital, he was with J.P. Morgan Partners, which he joined in April 2001 and of which he became a Partner in January 2005. From October 1998 to April 2001, he was in Business and Corporate Development at Genentech, Inc. (now a member of the Roche Group), a biotechnology company, most recently as Senior Manager. In addition to aTyr, Dr. Akkaraju serves as a director of Seattle Genetics, Intercept Pharmaceuticals, Inc. and Versartis, Inc., which are all publicly traded biotechnology companies. Previously, Dr. Akkaraju served as a director on the boards of ZS Pharma, Barrier Therapeutics, Inc., Eyetech Pharmaceuticals, Inc. and Synageva Biopharma Corp., all publicly traded biotechnology companies, and Amarin Corporation plc, a foreign publicly traded biotechnology company. Prior to joining Genentech, Dr. Akkaraju was a graduate student at Stanford University, where he received an M.D. and a Ph.D. in Immunology. He holds B.A.s in biochemistry and computer science from Rice University. .

James Blair

Dr. James C. Blair, Ph.D., is Independent Director of the Company. Dr. Blair has been a Partner of Domain Associates, a venture capital firm with a focus on life sciences, since the company’s founding in 1985. Present board memberships include Clovis Oncology, Inc., a biopharmaceutical company as well as numerous private company boards. Dr. Blair currently serves on the board of directors of the Prostate Cancer Foundation and the Sanford Burnham Prebys Medical Discovery Institute. He is also on the advisory boards of the Department of Molecular Biology at Princeton University, the USC Stevens Institute for Innovation, and the Division of Chemistry and Chemical Engineering at the California Institute of Technology. Dr. Blair holds a B.S.E. in electrical engineering from Princeton University and an M.S.E. and Ph.D. in electrical engineering from the University of Pennsylvania.

Amir Nashat

Dr. Amir H. Nashat, Ph.D., is Independent Director of the Company. He is also a Managing General Partner at Polaris Partners, a venture capital firm. He joined Polaris in April 2002 and focuses on investments in healthcare, consumer products and energy. Dr. Nashat is currently a director of Fate Therapeutics, Inc., Selecta Biosciences, Inc. and Syros Pharmaceuticals, Inc., all are publicly traded biopharmaceutical companies, as well as a director of several private companies. Additionally, Dr. Nashat has served as a director of Receptos, Inc. (acquired by Celgene Corporation), Adnexus Therapeutics, Inc. (acquired by Bristol-Myers Squibb Company) and other private companies. Dr. Nashat holds a Sc.D. in chemical engineering from the Massachusetts Institute of Technology with a minor in biology and an M.S. and B.S. in materials science and mechanical engineering from the University of California, Berkeley.

Paul Schimmel

Dr. Paul R. Schimmel, Ph.D., is Independent Director of the Company. Dr. Schimmel is currently a director of Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, as well as a director of several private companies. Dr. Schimmel is an Ernest and Jean Hahn Professor at The Skaggs Institute for Chemical Biology at The Scripps Research Institute. He was formerly the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics in the Department of Biology at the Massachusetts Institute of Technology. Dr. Schimmel holds a B.A. in biochemistry and biophysics from Ohio Wesleyan University and a Ph.D. from the Massachusetts Institute of Technology.

Basic Compensation